U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448194) titled 'A Phase Ia Clinical Trial of HW241045' on Feb. 25.
Brief Summary: This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.
Study Start Date: Nov. 24, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
IPF
Intervention:
DRUG: HW241045
Dose 1 to Dose 7
DRUG: Placebo
Dose 1 to Dose 7
Recruitment Status: RECRUITING
Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....